A Precision Oncology Scientist is a highly specialized researcher dedicated to advancing cancer treatment by tailoring therapies to the genetic and molecular profiles of individual patients. Through cutting-edge technologies such as next-generation sequencing (NGS), transcriptomics, and proteomics, these scientists analyze tumor DNA, RNA, and protein markers to uncover specific mutations and alterations that drive cancer growth. Their work is crucial for identifying actionable targets, developing biomarker-driven therapies, and stratifying patients for more effective and personalized treatment regimens. Precision oncology scientists collaborate closely with oncologists, pathologists, and bioinformaticians to translate complex molecular data into clinically relevant insights that guide therapeutic decisions.
In both academic and clinical research settings, Precision Oncology Scientists play a central role in drug discovery, biomarker validation, and clinical trial design. They often contribute to the development of companion diagnostics, monitor resistance mechanisms, and evaluate real-world patient responses to targeted therapies and immunotherapies. Their expertise is essential in advancing the promise of personalized medicine, where treatments are no longer one-size-fits-all but designed to match the unique biology of each patient’s cancer. As cancer care continues to evolve, the role of the precision oncology scientist becomes increasingly important in delivering more effective, less toxic, and ultimately life-saving treatments tailored to the individual patient.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China